This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Gildea, J. J. Articles by Theodorescu, D. Search for Related Content PubMed PubMed Citation Articles by Gildea, J. J. Articles by Theodorescu, D.

RhoGDI2 Is an Invasion and Metastasis Suppressor Gene in Human Cancer¹

Department of Molecular Physiology and Biological Physics, University of Virginia Health Sciences Center, Charlottesville, Virginia 22908 [J. J. G., M. J. S., G. O., M. A. H., D. T.]; Genomics Institute of the Novartis Research Foundation, San Diego, California 92121 [G. M. H.]; and Departments of Pathology [C. A. M., H. F. F.] and Health Evaluation Sciences (Biostatistics) [M. R. C.], University of Virginia Health Sciences Center, Charlottesville, Virginia 22908

	ABSTRACT

Top ABSTRACT Introduction Materials and Methods Results and Discussion REFERENCES

 
To discover novel metastasis suppressor genes that are clinically relevant in common human cancers, we used isogenic human bladder cancer cell lines and used DNA microarray technology to identify genes whose expression diminishes as a function of invasive and metastatic competence. We then evaluated the expression profile of such genes in 105 pathologically characterized tumors from seven common organ sites, and we identified one gene, RhoGDI2, whose expression was diminished as a function of primary tumor stage and grade. When RhoGDI2 was transferred back into cells with metastatic ability that lacked its expression, it suppressed experimental lung metastasis but did not affect in vitro growth, colony formation, or in vivo tumorigenicity. In addition, RhoGDI2 reconstitution in these cells blocked invasion in an organotypic assay and led to a reduction of in vitro motility. These results indicate that RhoGDI2 is a metastasis suppressor gene, a marker of aggressive human cancer, and a promising target for therapy.

	Introduction

Top ABSTRACT Introduction Materials and Methods Results and Discussion REFERENCES

 
Tumor cell growth at the site of metastasis is an important clinical target. Because cells must survive and proliferate to become overt metastases, there is ample opportunity for intervention. Understanding the genes responsible for either enhancing or suppressing this process would allow novel therapeutic and diagnostic applications to evolve and thus improve clinical care of cancer patients. However, although it takes the coordinated expression of many genes to allow the development of invasion and metastasis (1 , 2) , it may only take one gene to block this process because inability to complete any step of the metastatic cascade renders a cell nonmetastatic (3, 4, 5, 6) . Therefore, the discovery of metastasis suppressor genes (3, 4, 5, 6) , genes that inhibit the formation of spontaneous, macroscopic metastases without affecting the growth rate of the primary tumor, is critically important. In addition, at the time of their identification, strategies to define the relevance of such genes in human cancer progression would allow the prioritization of those whose expression is closely linked with this phenotype, thus accelerating the translational benefits to patient care afforded by such a discovery. In this study, we have used such a strategy to identify a novel metastasis suppressor gene in common human cancers.

	Materials and Methods

Top ABSTRACT Introduction Materials and Methods Results and Discussion REFERENCES

 
Cell Lines.
T24T is a highly metastatic, spontaneously occurring variant cell line of the human bladder cancer cell line T24. In contrast to this variant, T24 does not produce significant metastasis when injected i.v (7) .

Microarray Hybridization.
RNA extraction from cell lines and tissues was carried out as described previously (8) . For cell line analysis of gene expression, the HG-U133A Array (Affymetrix Inc., Santa Clara, CA) was used. RNA extraction from human tissues and hybridization on the U95Av2 GeneChip (Affymetrix) that represents 12,000 sequences, many of which have been previously characterized in terms of function or disease association, were performed as described previously (8) . We included only those probe sets whose maximum hybridization intensity (AD) in at least one sample was >200; the other probe sets were excluded (the quantification of gene transcripts with AD values uniformly <200 is typically unreliable).

Primary Tumor Analysis.
A set of 105 primary human carcinomas whose transcripts were profiled had known tumor stage and grade. This set of tumors comprised 24 prostate adenocarcinomas, 8 bladder carcinomas, 21 breast adenocarcinomas, 14 colorectal adenocarcinomas, 10 clear cell carcinomas of the kidney, 4 hepatocellular carcinomas, and 24 lung carcinomas.

Plasmid Constructs and Transfection and Derivation of Stable Cell Lines.
A full-length RhoGDI2 was cloned into the pCDNA 3.1-Zeo vector containing a zeocin-selectable marker driven by the cytomegalovirus promoter. Transfections of pCDNA 3.1-RhoGDI2 and pCDNA 3.1 were performed by Lipofectin (Life Technologies, Inc.) using the manufacturer’s instructions. One day after transfection, 25 µg/ml zeocin (Invitrogen) was added to the cultures and maintained until no further death (1 month) was observed in the cultures.

Western Blot Analysis.
Protein extracts were prepared from T24T/vector and T24T/RhoGDI2 cells grown to 80–90% confluence in 100-mm dishes. Western blotting was carried out as described previously (9) using commercial enhanced chemiluminescence reagents (SuperSignal West Femto; Pierce) and photographic film. Antibodies for intact RhoGDI2 were from Biosource, and antibodies for cleaved RhoGDI2 were from Imgenex. Positive control lysates of Jurkat cells treated with staurosporine were from BD Transduction.

In Vitro Growth and Colony Formation.
Single cell suspensions were obtained with cell counts performed using a model ZM Coulter Counter. Trypan blue staining was used to assess viability before plating of the cells. After incubation of 375, 750, 1500, and 3000 cells/well in 96-well plates for various times, cell numbers were estimated using the CyQUANT assay (Molecular Probes, Eugene, OR). Colony formation in agar by 1 x 10⁴ cells inoculated into each well of 24-well cell culture plates was carried out using routine methods (10) .

s.c. Tumorigenicity, Experimental Metastasis Assay, and Tissue Processing.
Six-week-old nude mice were obtained from the University of Virginia breeding facility and maintained strictly according to the NIH and institutional guidelines. Subcutaneous tumorigenicity was evaluated as described previously (11) . For experimental metastasis, mice were given an i.v. lateral tail vein injection with 10⁶ tumor cells suspended in 0.1 ml of SFM.³ In both assays, mice were examined and weighed every week. Tumors were measured weekly, and mice were euthanized 8 weeks after injection. At the time of euthanasia, the lungs and liver were removed by dissection away from adjacent organs and examined grossly and microscopically. Visual counting of lung metastases was carried out as described previously (11) .

Chemotaxis and Invasion Assays.
Baseline and EGF-induced migration were assessed by measuring the movement of cells into a scraped, acellular area or "wound assay" as described previously (9) . Briefly, cells were plated in DMEM-F12 media plus 5% serum and grown to 90% confluence, serum-starved for 24 h in HyQ-CCM1 media (Hyclone, Houston, TX), scraped with a pipette tip, and assayed over a 12-h time period with and without EGF. A time 0 control was taken by fixing wells immediately after scraping. The assay was terminated when the EGF-stimulated control wound was completely closed, which occurred at approximately 12 h. The cells were then fixed in 100% methanol and stained with crystal violet. Analysis of the wounds was performed by digitally capturing the wounded area using an Olympus Stereo dissecting scope as described previously (9) .

Bladder Organ Culture Invasion Assay.
We modified and optimized the assay described by Crook et al. (12) . Rats were anesthetized, and bladders harvested under sterile conditions. The bladder was detubularized and glued in 1 well of a 6-well plate, urothelium side up, with cyanoacetate glue. Fifty µl of trypsin EDTA in HBSS (Life Technologies, Inc. catalogue number 25200-056) were added to the bladder and incubated for 15 min at room temperature. The trypsin was gently aspirated from the edge of the bladder, and any residual trypsin was inactivated by 100 µl of 100% fetal bovine serum. The fetal bovine serum was removed, and 5 x 10⁵ cells in 100 µl of complete Waymouths media (Gibco) with 10% FCS containing antibiotic/antimycotic were placed on the bladder surface and incubated for 4 h. After 4 h, 4 ml of complete media were added to each well. The media were changed twice a week for the duration of the experiment. After 3 weeks, the bladders were washed twice with PBS and fixed overnight in 10% buffered formalin. Routine histological sections were carried out as described previously (10) and examined by a board-certified anatomical pathologist (C. A. M.).

	Results and Discussion

Top ABSTRACT Introduction Materials and Methods Results and Discussion REFERENCES

 
We have recently characterized a human bladder cancer cell line T24 and its more aggressive isogenic variant, T24T (7) . When injected i.v., T24 forms metastases in approximately one-third of mice with 1–2 lesions/mouse, whereas T24T produces metastases in all mice with a mean of 24–28 lesions/mouse. In addition, T24 cells are noninvasive in organ culture and orthotopic models, whereas T24T are invasive in both (data not shown). To identify putative invasion and metastasis suppressor genes, we evaluated the gene expression profiles of these cell lines with low and high metastatic ability, focusing on genes whose expression is significantly diminished in the more metastatic and invasive T24T variant.

RNA was extracted from these two cell lines and hybridized to HG-U133A Affymetrix oligonucleotide arrays consisting of two GeneChip arrays. These arrays contain almost 45,000 probe sets representing more than 39,000 transcripts derived from approximately 33,000 human genes.⁴ A total of 2,368 genes were differentially diminished in the metastatic cell line. Table 1 shows a summary list of the top 30 genes whose expression was most diminished. Interestingly, several of these genes are known to be IFN inducible, but their relationship to tumor invasion and metastasis is unknown. Others, such as the genes for the matrix components fibronectin, collagen (13) , and tissue inhibitor of metalloproteinase (14) , have known associations with tumor invasion and metastasis. Expression of fibronectin has been linked with metastasis in a melanoma model (15) , whereas other work has shown that fibronectin fragments can inhibit tumor growth, angiogenesis, and metastasis (16) .

Having uncovered 2368 genes whose expression patterns correlate with diminished invasion and metastasis in our cell line model, we used a secondary selection criteria to determine which genes warranted further mechanistic study, based on their expression levels in human tumors as a function of pathological stage and grade. We used the HG-U95Av2 GeneChip (Affymetrix) to determine the gene expression profiles of 105 primary human tumors whose stage and grade status were known. This set of tumors comprised the most common lethal human carcinomas from the following organ sites: 24 from lung; 24 from prostate; 21 from breast; 14 from colon and rectum; 10 from kidney; 8 from bladder; and 4 from liver. We sought to evaluate expression of our candidate metastasis suppressor genes in this cohort of tumors to determine their widespread importance in human cancer progression, rather than their association with progression of only a single histological type of carcinoma.

We then proceeded in descending order to evaluate the genes shown in Table 1 , and we found that RhoGDI2 was the first gene that correlated with both tumor stage and grade (Fig. 1A) . In addition, we have previously shown that expression of RhoGDI2 is inversely correlated with the invasive phenotype in human bladder cell lines (11) . Hence, the eight genes whose expression was found to be more diminished than RhoGDI2 in T24T cells were not uniformly related to both tumor grade and stage (Fig. 1A) and thus were not further investigated. Furthermore, in view of published evidence that overexpression and/or misregulation of Rho family members are associated with metastatic disease, we sought to evaluate such expression levels in our cohort of human tumors. As can be seen in Fig. 1B , among the genes present on the HG-U95Av2 array, only RhoGDI2 expression levels are associated with both tumor grade and stage.

View larger version (38K): [in this window] [in a new window]   Fig. 1. A, RhoGDI2 expression in human cancer correlates with grade and stage. A set of 105 primary carcinomas was expression profiled, and their clinicopathological data, including stage and grade, were assigned by a board-certified anatomical pathologist (H. F. F.). The expression level of the eight most diminished genes in the metastatic T24T cells is shown as a function of stage and grade. B, expression of Rho family GTPases in human cancer. Expression analysis as in A for genes encoding Rho family GTPases and their regulators found on the HG-U95Av2 array. C, RhoGDI2 expression in bladder cell lines. Western blot analysis of RhoGDI2 protein levels in whole cell lysates (10 µg protein/lane) for T24, T24T, and T24T vector- and RhoGDI2-transfected cells. Lanes are as indicated. Jurkat cell lysates are positive controls for cleaved RhoGDI2-specific antibody.

By definition, a metastasis suppressor gene does not affect growth or tumorigenicity; we evaluated these features in the vector control and RhoGDI2-transfected T24T cell lines. As can be seen in Fig. 2A , in vitro growth was not significantly different between the two cell lines. When anchorage-independent growth (clonogenicity in soft agar) was evaluated, no difference was seen (Fig. 2B) . Finally, tumorigenicity at s.c. sites in immunocompromised mice (Fig. 2C) was similar for both cell lines.

View larger version (28K): [in this window] [in a new window]   Fig. 2. RhoGDI2 transfection does not affect in vitro or in vivo growth. A, monolayer in vitro growth in medium containing 10% FCS of the vector- and RhoGDI2-transfected cell lines described in Fig. 1 is shown. B, soft agar colony formation. The transfected pools and clones were cultured in an agar suspension with 10% FCS. Representative figures are shown. C, s.c. in vivo growth. Eight nude mice were injected with either 106 vector- or RhoGDI2-transfected tumor cells suspended in 0.1 ml of SFM. Measurements of tumor size were carried out by the same observer, who was unaware of the identity of the cell lines producing the tumor, for the duration of the experiment. Each bar represents the mean ± SE. All experiments were carried out in duplicate on separate occasions with similar results.

View larger version (70K): [in this window] [in a new window]   Fig. 3. RhoGDI regulates bladder cancer metastasis, chemotaxis, and invasion. A, experimental metastasis. Eight nude mice were injected (tail vein) with either 106 vector- or RhoGDI2-transfected tumor cells suspended in 0.1 ml of SFM. At 8 weeks (or at time of death, if earlier), animals were autopsied, and organs were examined grossly and microscopically. B, chemotaxis. Control cells were incubated in SFM, and the assay was terminated when the EGF-stimulated control wound was completely closed, which occurred at approximately 12 h. Panels indicate typical fields used to quantitate motility. The final concentrations of reagents in the assay media were as follows: EGF, 10 ng/ml; and 30 µm LY294002 (LY). C, organotypic in vitro invasion. Histological analysis of H&E-stained (magnification, x100) whole bladder wall cultures after surface application of T24T cells transfected with vector or RhoGDI-expressing constructs. An aggressive muscle invasive bladder cancer generated by the vector control-transfected cell population is shown with blue arrows indicating the cells that have invaded the submucosa. A bladder slice showing superficial tumor generated by RhoGDI2-transfected cells is also shown. All experiments were carried out in duplicate or triplicate on separate occasions with similar results.

Using a novel organotypic bladder invasion assay, we evaluated the invasive ability of vector control- and RhoGDI2-transfected cell lines. As can be seen in Fig. 3B , the vector-transfected cell lines are invasive, as would be expected in view of their metastatic phenotype, whereas cells expressing the RhoGDI2 transgene remain superficial to the basement membrane, which is similar in behavior to their lineage-related noninvasive counterpart, T24 (data not shown).

Furthermore, because invasion is composed of several distinct steps (1) , a critical one being cell motility, we sought to refine our understanding of the mechanisms by which RhoGDI2 blocks invasion by evaluating the impact of RhoGDI2 reconstitution on the motile phenotype. Because EGF induces in vitro cell migration in T24 cells (9) and is a significant factor in the biology of invasive bladder cancer (23) , we examined the role of RhoGDI2 in EGF-induced cell migration. In the standard wound assay, cells expressing the RhoGDI2 transgene had poor baseline migration and a minimal response to EGF addition (Fig. 3C) . Because phosphatidylinositol 3'-kinase is a known mediator of EGF-mediated motility in these cells (9) , LY294002 was used as an additional specificity control for motility inhibition.

In summary, we have identified RhoGDI2 as a novel metastasis suppressor gene in human cancer. This gene is mechanistically involved in suppressing tumor invasion and metastasis in model systems of human bladder cancer, and its expression is diminished as a function of tumor stage and grade in a variety of common human carcinomas, suggesting an important and fundamental role in the pathogenesis of tumor progression in human cancer irrespective of tumor type. As mentioned above, the role of Rho proteins in cancer metastasis is growing (15) . The GDP-bound form of Rho family members is complexed with RhoGDIs and remains in the cytosol as an inactive form until their release from RhoGDI (24) . RhoGDI is a soluble protein, and it inhibits the association of the GDP-bound form of prenylated Rho with the membrane by forming a ternary complex (25) and thus limits the availability of Rho molecules to be converted from an inactive to an active (GDPGTP) form. Because Rho GTPases are strongly implicated in experimental metastasis of breast (26) and melanoma (15) cancer model as well as in human inflammatory breast cancer (19) , the inferred effect of decreased expression of a RhoGDI would be to provide increased access of Rho guanine nucleotide exchange factors to the Rho GTPases, thus allowing the cell to become more invasive and metastatic. In addition, our findings challenge the notion that expression of RhoGDI2 is specific to hematogenous cell lineages (27) .

This work also highlights the power and utility of combining gene profiling of well-defined experimental model systems with human data to pinpoint functionally relevant gene products in human disease. Although the in vivo specificity of RhoGDI2 for Rho protein targets remains to be determined, preliminary results indicate that it may regulate the activity of RhoB.⁵ These observations suggest important functional differences between Rho family members with respect to their role in cell motility, invasion, and metastasis. In addition, interpretation of the expression data from human tumors suggests that Rho family members may be actively involved in the metastatic cascade via deregulated activity from loss of GDI function, in addition to possible overexpression or activating mutations. One of the most important ramifications of this work concerns the therapeutic and diagnostic possibilities offered by these observations. There is a critical need for markers that will accurately distinguish those histological lesions with a high probability of causing clinically important metastatic disease from those that will remain indolent. Finally, because guanine nucleotide dissociation inhibitors such as RhoGDI2 function to block specific enzymatic reactions, high-throughput systems can be readily designed for discovery of mimetic agents that target such reactions.

	FOOTNOTES

 
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

¹ Supported by an American Foundation for Urologic Disease training grant (to J. J. G.), NIH Training Grant DK007766-02 (to G. O.), and NIH Grant CA075115 and Kimmel Foundation awards (to D. T.). The authors declare that they have no competing financial interests.

² To whom requests for reprints should be addressed, at Department of Molecular Physiology and Biological Physics, Box 422, University of Virginia Health Sciences Center, Charlottesville, VA 22908. Phone: (804) 924-0042; Fax: (804) 982-3652; E-mail: dt9d{at}virginia.edu

³ The abbreviations used are: SFM, serum-free medium; EGF, epidermal growth factor.

⁴ www.affymetrix.com.

⁵ G. Oxford and D. Theodorescu, unpublished observations.

Received 8/ 2/02. Accepted 9/30/02.

	REFERENCES

Top ABSTRACT Introduction Materials and Methods Results and Discussion REFERENCES

 

1. Liotta L. A., Kohn E. C. The microenvironment of the tumour-host interface. Nature (Lond.), 411: 375-379, 2001.[Medline]
2. Liotta L. A., Clair T. Cancer. Checkpoint for invasion. Nature (Lond.), 405: 287-288, 2000.
3. Leone A., Flatow U., King C. R., Sandeen M. A., Margulies I. M., Liotta L. A., Steeg P. S. Reduced tumor incidence, metastatic potential, and cytokine responsiveness of nm23-transfected melanoma cells. Cell, 65: 25-35, 1991.[Medline]
4. Dong J. T., Lamb P. W., Rinker-Schaeffer C. W., Vukanovic J., Ichikawa T., Isaacs J. T., Barrett J. C. KAI1, a metastasis suppressor gene for prostate cancer on human chromosome 11p11.2. Science (Wash. DC), 268: 884-886, 1995.[Abstract/Free Full Text]
5. Seraj M. J., Samant R. S., Verderame M. F., Welch D. R. Functional evidence for a novel human breast carcinoma metastasis suppressor, BRMS1, encoded at chromosome 11q13. Cancer Res, 60: 2764-2769, 2000.[Abstract/Free Full Text]
6. Yoshida B. A., Sokoloff M. M., Welch D. R., Rinker-Schaeffer C. W. Metastasis-suppressor genes: a review and perspective on an emerging field. J. Natl. Cancer Inst. (Bethesda), 92: 1717-1730, 2000.[Abstract/Free Full Text]
7. Gildea J. J., Golden W. L., Harding M. A., Theodorescu D. Genetic and phenotypic changes associated with the acquisition of tumorigenicity in human bladder cancer. Genes Chromosomes Cancer, 27: 252-263, 2000.[Medline]
8. Welsh J. B., Sapinoso L. M., Su A. I., Kern S. G., Wang-Rodriguez J., Moskaluk C. A., Frierson H. F., Jr., Hampton G. M. Analysis of gene expression identifies candidate markers and pharmacological targets in prostate cancer. Cancer Res., 61: 5974-5978, 2001.[Abstract/Free Full Text]
9. Gildea J. J., Harding M. A., Seraj M. J., Gulding K. M., Theodorescu D. The Role of Ral A in epidermal growth factor receptor-regulated cell motility. Cancer Res., 62: 982-985, 2002.[Abstract/Free Full Text]
10. Theodorescu D., Cornil I., Fernandez B. J., Kerbel R. S. Overexpression of normal and mutated forms of HRAS induces orthotopic bladder invasion in a human transitional cell carcinoma. Proc. Natl. Acad. Sci. USA, 87: 9047-9051, 1990.[Abstract/Free Full Text]
11. Seraj M. J., Harding M. A., Gildea J. J., Welch D. R., Theodorescu D. The relationship of BRMS1 and RhoGDI2 gene expression to metastatic potential in lineage related human bladder cancer cell lines. Clin. Exp. Metastasis, 18: 519-525, 2000.[Medline]
12. Crook T. J., Hall I. S., Solomon L. Z., Birch B. R., Cooper A. J. A model of superficial bladder cancer using fluorescent tumour cells in an organ-culture system. BJU Int., 86: 886-893, 2000.[Medline]
13. Zhuge Y., Xu J. Rac1 mediates type I collagen-dependent MMP-2 activation. Role in cell invasion across collagen barrier. J. Biol. Chem., 276: 16248-16256, 2001.[Abstract/Free Full Text]
14. Baker A. H., Zaltsman A. B., George S. J., Newby A. C. Divergent effects of tissue inhibitor of metalloproteinase-1, -2, or -3 overexpression on rat vascular smooth muscle cell invasion, proliferation, and death in vitro. TIMP-3 promotes apoptosis. J. Clin. Investig., 101: 1478-1487, 1998.[Medline]
15. Clark E. A., Golub T. R., Lander E. S., Hynes R. O. Genomic analysis of metastasis reveals an essential role for RhoC. Nature (Lond.), 406: 532-535, 2000.[Medline]
16. Yi M., Ruoslahti E. A fibronectin fragment inhibits tumor growth, angiogenesis, and metastasis. Proc. Natl. Acad. Sci. USA, 98: 620-624, 2001.[Abstract/Free Full Text]
17. Jaffe A. B., Hall A. Rho GTPases in transformation and metastasis. Adv. Cancer Res., 84: 57-80, 2002.[Medline]
18. Ridley A. Molecular switches in metastasis. Nature (Lond.), 406: 466-467, 2000.[Medline]
19. van Golen K. L., Bao L. W., Pan Q., Miller F. R., Wu Z. F., Merajver S. D. Mitogen activated protein kinase pathway is involved in RhoC GTPase induced motility, invasion and angiogenesis in inflammatory breast cancer. Clin. Exp. Metastasis, 19: 301-311, 2002.[Medline]
20. Yoshioka K., Matsumura F., Akedo H., Itoh K. Small GTP-binding protein Rho stimulates the actomyosin system, leading to invasion of tumor cells. J. Biol. Chem., 273: 5146-5154, 1998.[Abstract/Free Full Text]
21. Michiels F., Habets G. G., Stam J. C., van der Kammen R. A., Collard J. G. A role for Rac in Tiam1-induced membrane ruffling and invasion. Nature (Lond.), 375: 338-340, 1995.[Medline]
22. Van Aelst L., D’Souza-Schorey C. Rho GTPases and signaling networks. Genes Dev., 11: 2295-2322, 1997.[Free Full Text]
23. Smith K., Fennelly J. A., Neal D. E., Hall R. R., Harris A. L. Characterization and quantitation of the epidermal growth factor receptor in invasive and superficial bladder tumors. Cancer Res., 49: 5810-5815, 1989.[Abstract/Free Full Text]
24. Sasaki T., Takai Y. The Rho small G protein family-Rho GDI system as a temporal and spatial determinant for cytoskeletal control. Biochem. Biophys. Res. Commun., 245: 641-645, 1998.[Medline]
25. Isomura M., Kikuchi A., Ohga N., Takai Y. Regulation of binding of rhoB p20 to membranes by its specific regulatory protein, GDP dissociation inhibitor. Oncogene, 6: 119-124, 1991.[Medline]
26. Bourguignon L. Y., Zhu H., Shao L., Chen Y. W. Ankyrin-Tiam1 interaction promotes Rac1 signaling and metastatic breast tumor cell invasion and migration. J. Cell Biol., 150: 177-191, 2000.[Abstract/Free Full Text]
27. Lelias J. M., Adra C. N., Wulf G. M., Guillemot J. C., Khagad M., Caput D., Lim B. cDNA cloning of a human mRNA preferentially expressed in hematopoietic cells and with homology to a GDP-dissociation inhibitor for the rho GTP-binding proteins. Proc. Natl. Acad. Sci. USA, 90: 1479-1483, 1993.[Abstract/Free Full Text]

This article has been cited by other articles:

				P. Matos and P. Jordan Increased Rac1b Expression Sustains Colorectal Tumor Cell Survival Mol. Cancer Res., July 1, 2008; 6(7): 1178 - 1184. [Abstract] [Full Text] [PDF]

				D. C. Lee, Y. K. Kang, W. H. Kim, Y. J. Jang, D. J. Kim, I. Y. Park, B. H. Sohn, H. A. Sohn, H. G. Lee, J. S. Lim, et al. Functional and Clinical Evidence for NDRG2 as a Candidate Suppressor of Liver Cancer Metastasis Cancer Res., June 1, 2008; 68(11): 4210 - 4220. [Abstract] [Full Text] [PDF]

				D. Schunke, P. Span, H. Ronneburg, A. Dittmer, M. Vetter, H.-J. Holzhausen, E. Kantelhardt, S. Krenkel, V. Muller, F. C.G.J. Sweep, et al. Cyclooxygenase-2 Is a Target Gene of Rho GDP Dissociation Inhibitor {beta} in Breast Cancer Cells Cancer Res., November 15, 2007; 67(22): 10694 - 10702. [Abstract] [Full Text] [PDF]

				Z Wu, K. McRoberts, and D Theodorescu The role of PTEN in prostate cancer cell tropism to the bone micro-environment Carcinogenesis, July 1, 2007; 28(7): 1393 - 1400. [Abstract] [Full Text] [PDF]

				T. Cavanna, E. Pokorna, P. Vesely, C. Gray, and D. Zicha Evidence for protein 4.1B acting as a metastasis suppressor J. Cell Sci., February 15, 2007; 120(4): 606 - 616. [Abstract] [Full Text] [PDF]

				C. DerMardirossian, G. Rocklin, J.-Y. Seo, and G. M. Bokoch Phosphorylation of RhoGDI by Src Regulates Rho GTPase Binding and Cytosol-Membrane Cycling Mol. Biol. Cell, November 1, 2006; 17(11): 4760 - 4768. [Abstract] [Full Text] [PDF]

				C. W. Rinker-Schaeffer, J. P. O'Keefe, D. R. Welch, and D. Theodorescu Metastasis Suppressor Proteins: Discovery, Molecular Mechanisms, and Clinical Application. Clin. Cancer Res., July 1, 2006; 12(13): 3882 - 3889. [Full Text] [PDF]

				Y. Zhang and B. Zhang D4-GDI, a Rho GTPase Regulator, Promotes Breast Cancer Cell Invasiveness Cancer Res., June 1, 2006; 66(11): 5592 - 5598. [Abstract] [Full Text] [PDF]

				B. Titus, H. F. Frierson Jr., M. Conaway, K. Ching, T. Guise, J. Chirgwin, G. Hampton, and D. Theodorescu Endothelin Axis Is a Target of the Lung Metastasis Suppressor Gene RhoGDI2 Cancer Res., August 15, 2005; 65(16): 7320 - 7327. [Abstract] [Full Text] [PDF]

				N Nathoo, A Chahlavi, G H Barnett, and S A Toms Pathobiology of brain metastases J. Clin. Pathol., March 1, 2005; 58(3): 237 - 242. [Abstract] [Full Text] [PDF]

				T Yanagawa, T Funasaka, S Tsutsumi, H Watanabe, and A Raz Novel roles of the autocrine motility factor/phosphoglucose isomerase in tumor malignancy Endocr. Relat. Cancer, December 1, 2004; 11(4): 749 - 759. [Abstract] [Full Text] [PDF]

				B. E. Nicholson, H. F. Frierson, M. R. Conaway, J. M. Seraj, M. A. Harding, G. M. Hampton, and D. Theodorescu Profiling the Evolution of Human Metastatic Bladder Cancer Cancer Res., November 1, 2004; 64(21): 7813 - 7821. [Abstract] [Full Text] [PDF]

				D. Theodorescu, L. M. Sapinoso, M. R. Conaway, G. Oxford, G. M. Hampton, and H. F. Frierson Jr. Reduced Expression of Metastasis Suppressor RhoGDI2 Is Associated with Decreased Survival for Patients with Bladder Cancer Clin. Cancer Res., June 1, 2004; 10(11): 3800 - 3806. [Abstract] [Full Text] [PDF]

				P. S. Steeg PERSPECTIVES ON CLASSIC ARTICLES: Metastasis Suppressor Genes J Natl Cancer Inst, March 17, 2004; 96(6): E4 - E4. [Full Text]

				K. Wennerberg and C. J. Der Rho-family GTPases: it's not only Rac and Rho (and I like it) J. Cell Sci., March 15, 2004; 117(8): 1301 - 1312. [Abstract] [Full Text] [PDF]

				C.-C. Chang, J.-Y. Shih, Y.-M. Jeng, J.-L. Su, B.-Z. Lin, S.-T. Chen, Y.-P. Chau, P.-C. Yang, and M.-L. Kuo Connective Tissue Growth Factor and Its Role in Lung Adenocarcinoma Invasion and Metastasis J Natl Cancer Inst, March 3, 2004; 96(5): 364 - 375. [Abstract] [Full Text] [PDF]

				P. Matos, J. G. Collard, and P. Jordan Tumor-related Alternatively Spliced Rac1b Is Not Regulated by Rho-GDP Dissociation Inhibitors and Exhibits Selective Downstream Signaling J. Biol. Chem., December 12, 2003; 278(50): 50442 - 50448. [Abstract] [Full Text] [PDF]

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Gildea, J. J. Articles by Theodorescu, D. Search for Related Content PubMed PubMed Citation Articles by Gildea, J. J. Articles by Theodorescu, D.